Duff & Phelps Investment Management Co. lowered its position in Johnson & Johnson (NYSE:JNJ) by 3.0% during the second quarter, Holdings Channel reports. The fund owned 35,725 shares of the company’s stock after selling 1,090 shares during the period. Duff & Phelps Investment Management Co.’s holdings in Johnson & Johnson were worth $4,333,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Perigon Wealth Management LLC increased its stake in Johnson & Johnson by 5.0% in the fourth quarter. Perigon Wealth Management LLC now owns 35,295 shares of the company’s stock worth $3,625,000 after buying an additional 1,681 shares during the last quarter. Pioneer Investment Management Inc. boosted its position in Johnson & Johnson by 60.6% in the fourth quarter. Pioneer Investment Management Inc. now owns 3,824,174 shares of the company’s stock worth $392,819,000 after buying an additional 1,442,984 shares during the period. Strategic Wealth Advisors Group Inc. boosted its position in Johnson & Johnson by 12.6% in the fourth quarter. Strategic Wealth Advisors Group Inc. now owns 15,490 shares of the company’s stock worth $1,592,000 after buying an additional 1,728 shares during the period. Reliance Trust Co. of Delaware boosted its position in Johnson & Johnson by 5.0% in the fourth quarter. Reliance Trust Co. of Delaware now owns 191,728 shares of the company’s stock worth $19,695,000 after buying an additional 9,176 shares during the period. Finally, Sonora Investment Management LLC boosted its position in Johnson & Johnson by 20.5% in the fourth quarter. Sonora Investment Management LLC now owns 36,346 shares of the company’s stock worth $3,733,000 after buying an additional 6,171 shares during the period. Institutional investors own 65.31% of the company’s stock.

Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.50% on Monday, reaching $117.66. The company had a trading volume of 5,457,633 shares. The company has a 50-day moving average price of $120.64 and a 200-day moving average price of $116.04. The firm has a market capitalization of $321.90 billion, a PE ratio of 21.93 and a beta of 0.61. Johnson & Johnson has a 52-week low of $89.90 and a 52-week high of $126.07.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, July 19th. The company reported $1.74 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.68 by $0.06. Johnson & Johnson had a return on equity of 24.70% and a net margin of 20.97%. The business earned $18.50 billion during the quarter, compared to analyst estimates of $17.98 billion. Equities research analysts forecast that Johnson & Johnson will post $6.69 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd were issued a dividend of $0.80 per share. The ex-dividend date of this dividend was Friday, August 19th. This represents a $3.20 annualized dividend and a dividend yield of 2.72%. Johnson & Johnson’s dividend payout ratio is 60.15%.

A number of research firms have recently weighed in on JNJ. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $133.00 price target for the company in a report on Tuesday, September 13th. Jefferies Group cut their price target on Johnson & Johnson from $119.00 to $115.00 and set a “hold” rating for the company in a report on Tuesday, September 13th. Leerink Swann reissued a “buy” rating on shares of Johnson & Johnson in a report on Sunday, September 11th. BTIG Research reissued a “neutral” rating on shares of Johnson & Johnson in a report on Wednesday, September 7th. Finally, Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $124.21 price target for the company in a report on Monday, August 22nd. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and twelve have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $119.10.

In related news, VP Dominic J. Caruso sold 41,146 shares of the stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the completion of the sale, the vice president now directly owns 157,819 shares in the company, valued at $19,728,953.19. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CAO Ronald A. Kapusta sold 2,935 shares of the stock in a transaction on Friday, July 22nd. The stock was sold at an average price of $125.01, for a total value of $366,904.35. Following the sale, the chief accounting officer now owns 28,660 shares of the company’s stock, valued at $3,582,786.60. The disclosure for this sale can be found here. Corporate insiders own 0.11% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.